Institutional investors purchased a net $317.9 thousand shares of IMGN during the quarter ended March 2017 and now own 76.41% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
REDMILE GROUP LLC Bought 4.0 Million shares of ImmunoGen Inc
CLEARBRIDGE INVESTMENTS LLC Bought 884.5 Thousand shares of ImmunoGen Inc
COLUMBIA MANAGEMENT INVESTMENT A... Bought 393.0 Thousand shares of ImmunoGen Inc